Form 4: Apogee CEO Michael Henderson Sells 20,000 Shares
Statement of Changes in Beneficial Ownership
Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.
Summary
- CEO Michael Henderson sold a total of 20,000 shares of Apogee Therapeutics common stock on May 13, 2026.
- The sales were executed in two tranches: 18,659 shares at a weighted average price of $82.05 and 1,341 shares at a weighted average price of $82.58.
- Following these transactions, the CEO retains beneficial ownership of 1,115,987 shares.
- The transactions were conducted under a Rule 10b5-1 trading plan adopted on August 13, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed via a pre-planned 10b5-1 program, which is standard practice for executive financial planning.
Positives
- The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering concerns regarding insider information.
Negatives
- The sale represents a reduction in the CEO's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by the market, potentially impacting short-term investor sentiment.
Future Outlook
No forward-looking guidance regarding company operations or financial performance was provided in this filing.
Industry Context
StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine in the biotechnology sector and generally do not signal a change in corporate strategy or outlook.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate executives to manage personal liquidity while maintaining compliance with SEC regulations.
Stakeholder Impact
- Shareholders should note the reduction in insider holdings, though the pre-planned nature of the sale mitigates concerns regarding insider sentiment.
Key Dates
| Date | Description |
|---|---|
| 2025-08-13 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-05-13 | Date of the reported stock sales. |
| 2026-05-15 | Date the Form 4 was signed and filed. |
Keywords
Apogee Therapeutics, APGE, Insider Trading, Form 4, Michael Henderson, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.